methylprednisolone and Bone Marrow Neoplasms

methylprednisolone has been researched along with Bone Marrow Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Annus, JK; Borbényi, Z; Marton, I; Nemes, A; Pósfai, É; Vecsei, L; Vörös, E	1
Bosq, J; Cartron, G; Casasnovas, O; Chassagne-Clément, C; Coiffier, B; Cornillon, J; Dombret, H; Fornecker, LM; Ghesquieres, H; Girault, S; Koscielny, S; Lamy, T; Le Gouill, S; Leguay, T; Mariette, C; Morschhauser, F; Ojeda-Uribe, M; Recher, C; Ribrag, V; Salles, G; Tilly, H; Verge, V	1

Trials

1 trial(s) available for methylprednisolone and Bone Marrow Neoplasms

Article	Year
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet (London, England), 2016, Jun-11, Volume: 387, Issue:10036 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; France; Humans; Hydrocortisone; Injections, Intravenous; Male; Methotrexate; Methylprednisolone; Middle Aged; Neoplasm Staging; Odds Ratio; Patient Selection; Prednisone; Proportional Hazards Models; Rituximab; Treatment Outcome; Vincristine	2016

Article

Year

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Lancet (London, England), 2016, Jun-11, Volume: 387, Issue:10036

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; France; Humans; Hydrocortisone; Injections, Intravenous; Male; Methotrexate; Methylprednisolone; Middle Aged; Neoplasm Staging; Odds Ratio; Patient Selection; Prednisone; Proportional Hazards Models; Rituximab; Treatment Outcome; Vincristine

2016

Other Studies

1 other study(ies) available for methylprednisolone and Bone Marrow Neoplasms

Article	Year
WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM. Ideggyogyaszati szemle, 2015, May-30, Volume: 68, Issue:5-6 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Neoplasms; Cardiomyopathies; Central Nervous System Diseases; Diagnosis, Differential; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infarction; Magnetic Resonance Imaging; Male; Methylprednisolone; mRNA Cleavage and Polyadenylation Factors; Neuroprotective Agents; Piperazines; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2015

Article

Year

WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN FIP1L1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM.

Ideggyogyaszati szemle, 2015, May-30, Volume: 68, Issue:5-6

Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Neoplasms; Cardiomyopathies; Central Nervous System Diseases; Diagnosis, Differential; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Infarction; Magnetic Resonance Imaging; Male; Methylprednisolone; mRNA Cleavage and Polyadenylation Factors; Neuroprotective Agents; Piperazines; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha

2015